Pharmacology Watch – November 1, 2015
November 1, 2015
View Issues
-
Diabetes Drug Reduces Heart Failure, Cardiovascular Death Risk
Patients with type 2 diabetes at high risk for cardiovascular disease who received empagliflozin had significantly lower rates of the composite cardiac vascular outcome and death from any cause.
-
CDC Issues New Guidelines for Pneumococcal Vaccines
The time interval between the two vaccines improves the immune response.
-
Study: Delay Shingles Vaccine to Age 60
The shingles vaccine does not represent a good value for patients at age 50 years, according to generally accepted standards.
-
Spironolactone Effective Add-on for Resistant Hypertension Patients
Spironolactone was the most effective add-on drug for treatment of resistant hypertension, suggesting that sodium retention plays a role in this condition.
-
FDA Actions
FDA strengthens warning about canagliflozin, approves cariprazine to treat schizophrenia and bipolar disorder, and green lights insulin degludec, a new long-acting insulin analog.